Beren Therapeutics raised an undisclosed amount for the development of Adrabetadex, a treatment for Niemann-Pick disease type C (NPC).
Beren Therapeutics raised an undisclosed amount for the development of Adrabetadex, a treatment for Niemann-Pick disease type C (NPC).